17,261 trials
Major Depressive Disorder
Primary: Part A: Change in MADRS Score at 1 Day the Initial Dose of AGN-241751 Reported as Change From Baseline in Treated Group Compared With Change From Baseline in Placebo…
Solid Tumor · Leiomyosarcoma · Osteosarcoma
Primary: Changes in Phospho-Chk1 Levels in Biopsy Specimens — 156; 196; 89; 84 percent change
Breast Cancer · Head and Neck Squamous Cell Carcinoma · Colorectal Cancer
Primary: Measure Mean Fluorescence Intensity of Histologically Confirmed Tumor vs Normal Tissue in Patients Undergoing Routine Surgery [Tumor to Background Ratio (TBR)] — 1.098…
HIV-1 Infection
Primary: Change From Baseline in Copies of HIV DNA Per CD4+ T Cell at Week 24 — 113; 98 HIV DNA copies per CD4+ T cell — p=0.0797
Chronic Kidney Disease
Primary: Change From Baseline in Mean 24-Hour Urine Total Protein Level at Week 6 — 2.07; 2.07; 1.95; -0.62 Grams per 24 hours — p=0.0040
Pancreas Cancer
Primary: Progression-Free Survival (PFS) — 1.49 months
NonSegmental Vitiligo
Primary: Percent Change From Baseline in Total Vitiligo Area Scoring Index (T-VASI) at Week 24 — 2.29; -19.12; -17.78; -15.73 percent change — p=0.0015
Acute Lymphoblastic Leukemia
Primary: Pharmacokinetics Measurement — 362028.656; 352248.907 mU*day/mL — p=0.05
Type 2 Diabetes
Primary: Change From Baseline in Hemoglobin A1c (HbA1c) — -0.05; -1.41; -0.43; -1.39 percentage of HbA1c — p=0.188
Neuromuscular Blockade · Renal Impairment
Primary: Time Until Complete Reversal of Neuromuscular Blockade — 14.8; 3.5 Minutes
Blood Pressure · End Stage Renal Disease on Dialysis (Diagnosis) · Chronic Kidney Diseases
Primary: Feasibility - Screen:Enrollment Ratio — 50 Participants
End Stage Renal Disease Requiring Hemodialysis
Primary: Incidence of Composite of Major Bleeding (MB) and Clinically-relevant Non-major Bleeding (CRNMB) During the Main Treatment Period and Within the On-treatment Time…
Pancreatic Adenocarcinoma
Primary: Rate of Progression-free Survival at 6 Months (PFS6) — 20.6; 59.6 percentage of participants with PFS
Recurrent Respiratory Papillomatosis
Primary: Overall Response Rate Via Endoscopic Lesional Burden Score and/or RECIST — 21 Participants
Seborrheic Dermatitis
Primary: Achievement of Investigator Global Assessment (IGA) Success at Week 8 — 104; 27 Participants — p=<0.0001